Session Description
Oncocytic cancers constitute about 3-4% of differentiated thyroid cancers. They were reclassified by WHO in 2022, due to a growing recognition that these cancers have unique biology and are not just a subset of follicular cancers. Upcoming revised ATA thyroid cancer and nodules guidelines (which will likely be published between now and ENDO 2025) are expected to provide separate recommendations for management, rather than lumping these with other DTCs. The session would cover the use/interpretation of molecular marker testing preoperatively, whether there is any utility of radioactive iodine treatment, postoperative surveillance strategies, and management of advanced disease, including focal therapies for bone metastases and other oligometastatic disease and systemic therapy with VEGFR multikinase inhibitors.